Blood test may predict immunotherapy success in cancer patients
NCT ID NCT06630429
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 23 times
Summary
This study is looking at whether changes in a blood test called tumor fraction can help predict how well immunotherapy works in people with non-small cell lung cancer or kidney cancer. About 100 adults are taking part, and researchers will also look at inflammation, hormone levels, and gut bacteria. The goal is to better understand who benefits from treatment, not to test a new therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.